Novel approaches to support therapeutic development in ultra-rare cancers
Agency: Food and Drug Administration
- 93.103 -- Food and Drug Administration Research
Forecasted opportunityLast Updated: May 13, 2026
Important dates
- Forecasted post date: Not specified
- Forecasted application due date: Not specified
- Forecasted award date: Not specified
- Forecasted project start date: Not specified
- Fiscal Year: 2026
Award details
- Expected project funding: Not specified
- Expected awards: 2
Award min.
Not specified
Award max.
Not specified
- Funding opportunity number:FOR-FD-26-004
- Cost sharing or matching requirement:No
- Funding instrument type:
- Cooperative agreement
- Opportunity Category:Discretionary
- Opportunity Category Explanation:Not specified
- Category of Funding Activity:
- Agriculture
- Consumer protection
- Food and nutrition
- Category Explanation:Not specified
History
- Forecast posted date: August 4, 2025
- Archive date: Not specified
- Version: 2
Summary
The purpose of this program is to support new approaches that can be applied to facilitate therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers.
Specific areas of interest include, but are not limited to, the following examples:
• Development of infrastructure for a coordination network and data repository for patient-level data across institutions and internationally to support drug development and regulatory decision-making for one or more ultra-rare cancers.
• Investigations to explore opportunities to develop and validate early clinical endpoints and other novel efficacy endpoints for evaluation of treatments for ultra-rare cancers.
• Development and implementation of a collaborative multi-stakeholder effort to support generation and use of real-world data leveraging a registry framework for use in development of new therapies for pediatric patients with diffuse midline glioma (DMG) (including diffuse intrinsic pontine glioma, DIPG).
• Innovative approaches to identify new biologically-driven opportunities for clinical development of previously approved drugs or biologics (hereafter referred to as drugs), including drugs for which development has been discontinued, in ultra-rare cancers.
• Research to develop novel approaches to preserve the availability of drugs for which commercial developers have discontinued adult development that have strong potential in ultra-rare cancers but lack financial incentives for commercial development
• Development of methods to incorporate use of telemedicine and/or pragmatic trial design elements (e.g., collecting laboratory and/or imaging data from local facilities) for patient assessments to facilitate enrollment of patients with ultra-rare cancers
• Development of nanoparticle-based delivery approaches for therapeutic nucleic acids targeting onco-fusion transcription factors in metastatic tumor animal models using targeted bioPROTAC degradation or genomic editing strategies. Successful efforts should demonstrate effective delivery and expression in-vivo to tumor cells, and downregulation of the target transcription factor protein while minimizing off-target effects and limiting sequestration of the nanoparticle by the liver, spleen, and lungs.
• Research to exhaustively characterize the plasma-membrane protein expression (surfaceome) of an ultra-rare cancer and the presumed healthy tissue of origin, as well as the resident-tissue stem cells, by single-cell transcriptomics and proteomics. These studies, and available correlative database analyses, should be designed to identify possible combinatorial signatures of plasma membrane proteins unique to the ultra-rare tumor. Tumors of interest include Sclerosing epithelioid fibrosarcoma and atypical teratoid rhabdoid tumors (ATRT).
Eligibility
Education
- Independent school districts
- Public and state institutions of higher education
- Private institutions of higher education
Government
- State governments
- Federally recognized Native American tribal governments
- County governments
- Public and Indian housing authorities
- Special district governments
- City or township governments
Nonprofit
- Nonprofits non-higher education without 501(c)(3)
- Other Native American tribal organizations
- Nonprofits non-higher education with 501(c)(3)
Business
- For-profit organizations other than small businesses
- Small businesses
Additional information on eligibility
Documents
No documents are currently available.
Agency contact information
Email: patrick.johnson@fda.hhs.gov
Contact FDA About this Opportunity
Link to additional information
No additional information is available
